Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price84.00 USD
Fair value163.00
Ethical score95.6/100
RatingFAIR VALUE
Our investment reviews on this name
2026-07-02Read Markup88.28-4.8% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Celcuity Inc. holds its Markdown at $84.00. The statistical read favours the sellers, held for 25 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 25 days
Price at the screen
$84.00
Valuation
N/A trailing · -1,068.63 forward price to earnings
Values screen
PASS· score 95.6
Beta
0.20
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
4.94%
Below 33%
Interest-bearing debt is just 4.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
6.78%
Below 33%
Cash held in interest-bearing accounts and securities is 6.8% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads FAIR VALUE: it trades at roughly a 94% discount to our $163.00 fair value.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 94.0% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +94% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech bet on one drug hits fair value
Picture a lab team pinning everything on one molecule that might slow aggressive tumours. Celcuity has reached that point with Gedatolisib yet still burns cash and shows no profit, so the shares trade right at our calculated worth with almost no margin of safety.
The market already hands the stock a strong buy label and a much higher target price, yet the forward multiple sits above 92 times while return on equity remains deeply negative. Ethical screens clear the company, which removes one usual reason to step aside, but the business remains a pure clinical bet.
Risks sit in plain sight: zero current earnings, heavy dilution ahead and the usual late-stage trial failures that can wipe out most of the value overnight. At current levels the price simply matches the numbers rather than offering any cushion. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CELC trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-24Markup$93.25+5.5%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169.
2026-07-24Markup$88.38+0.1%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169.
2026-07-18Markup$88.28+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169.
2026-07-03Markup$88.28+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (96). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$88.28Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (96). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
